News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,351 Results
Type
Article (43694)
Company Profile (473)
Press Release (694172)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209320)
Career Advice (2039)
Deals (36151)
Drug Delivery (119)
Drug Development (83971)
Employer Resources (174)
FDA (16693)
Job Trends (15189)
News (354163)
Policy (33279)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2657)
Accelerated approval (36)
Adcomms (28)
Allergies (146)
Alliances (51111)
ALS (178)
Alzheimer's disease (1729)
Antibody-drug conjugate (ADC) (330)
Approvals (16931)
Artificial intelligence (547)
Autoimmune disease (161)
Automation (39)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (654)
Cancer (4947)
Cardiovascular disease (418)
Career advice (1724)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (784)
Cervical cancer (36)
Clinical research (71460)
Collaboration (1804)
Company closure (4)
Compensation (1185)
Complete response letters (66)
COVID-19 (2772)
CRISPR (98)
C-suite (888)
Cystic fibrosis (152)
Data (6334)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (505)
Diagnostics (6753)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (270)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (245)
Earnings (91462)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121027)
Executive appointments (1008)
FDA (19854)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1537)
Gene editing (214)
Generative AI (45)
Gene therapy (649)
GLP-1 (1011)
Government (4760)
Grass and pollen (6)
Guidances (384)
Healthcare (19206)
HIV (60)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (275)
Immuno-oncology (62)
Indications (111)
Infectious disease (3048)
Inflammatory bowel disease (199)
Inflation Reduction Act (17)
Influenza (119)
Intellectual property (254)
Interviews (315)
IPO (16932)
IRA (53)
Job creations (3713)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (33)
Legal (8026)
Liver cancer (93)
Longevity (14)
Lung cancer (668)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (813)
MASH (171)
Medical device (13922)
Medtech (13975)
Mergers & acquisitions (20300)
Metabolic disorders (1322)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (341)
Neuropsychiatric disorders (97)
Neuroscience (3023)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4585)
Now hiring (67)
Obesity (633)
Opinion (282)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (233)
Parkinson's disease (295)
Partnered (34)
Patents (500)
Patient recruitment (504)
Peanut (57)
People (60326)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22474)
Phase 2 (31505)
Phase 3 (23293)
Pipeline (5361)
Policy (298)
Postmarket research (2602)
Preclinical (9607)
Press Release (67)
Prostate cancer (246)
Psychedelics (56)
Radiopharmaceuticals (298)
Rare diseases (896)
Real estate (6064)
Recruiting (71)
Regulatory (25018)
Reports (53)
Research institute (2486)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (78)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (104)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3805)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1036)
Venture capital (95)
Weight loss (410)
Women's health (93)
Worklife (19)
Date
Today (44)
Last 7 days (574)
Last 30 days (2098)
Last 365 days (30686)
2026 (3576)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40710)
Australia (6763)
California (11516)
Canada (3314)
China (1144)
Colorado (487)
Connecticut (497)
Delaware (339)
Europe (89241)
Florida (1700)
Georgia (359)
Hawaii (3)
Idaho (61)
Illinois (886)
India (66)
Indiana (527)
Iowa (24)
Japan (438)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1407)
Massachusetts (8370)
Michigan (327)
Minnesota (641)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3064)
New Mexico (31)
New York (3017)
North Carolina (1535)
North Dakota (9)
Northern California (5604)
Ohio (338)
Oklahoma (21)
Oregon (45)
Pennsylvania (2307)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4466)
Tennessee (175)
Texas (1771)
United States (40957)
Utah (340)
Vermont (1)
Virginia (268)
Washington D.C. (82)
Washington State (956)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
738,351 Results for "alaunos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
June 23, 2025
·
3 min read
Business
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023.
November 14, 2023
·
9 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Lone Star Bio
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
March 29, 2023
·
1 min read
Business
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
Alaunos Therapeutics, Inc., announced financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
8 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Press Releases
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
February 12, 2026
·
6 min read
Lone Star Bio
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
Alaunos Therapeutics, Inc. today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023.
June 29, 2023
·
2 min read
Press Releases
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
February 10, 2026
·
7 min read
Business
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
Alaunos Therapeutics, Inc., a leading T-cell receptor cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
May 10, 2023
·
9 min read
1 of 73,836
Next
